(3R,4S)-3-amino-1-(2-aminocyclopropyl)oxysulfonyl-4-(3-boronopropyl)pyrrolidine-3-carboxylic acid
C11H22BN3O7S — CID 155627301
Data last refreshed: (MolForge compound catalog, from PubChem)
About (3R,4S)-3-amino-1-(2-aminocyclopropyl)oxysulfonyl-4-(3-boronopropyl)pyrrolidine-3-carboxylic acid
(3R,4S)-3-amino-1-(2-aminocyclopropyl)oxysulfonyl-4-(3-boronopropyl)pyrrolidine-3-carboxylic acid (PubChem CID 155627301) has the molecular formula C11H22BN3O7S and a molecular weight of 351.19 g/mol. Its IUPAC name is (3R,4S)-3-amino-1-(2-aminocyclopropyl)oxysulfonyl-4-(3-boronopropyl)pyrrolidine-3-carboxylic acid.
Molecular Properties
| Compound Name | (3R,4S)-3-amino-1-(2-aminocyclopropyl)oxysulfonyl-4-(3-boronopropyl)pyrrolidine-3-carboxylic acid |
|---|---|
| PubChem CID | 155627301 |
| Molecular Formula | C11H22BN3O7S |
| Molecular Weight | 351.19 g/mol |
| Exact Mass | 351.13 |
| IUPAC Name | (3R,4S)-3-amino-1-(2-aminocyclopropyl)oxysulfonyl-4-(3-boronopropyl)pyrrolidine-3-carboxylic acid |
| SMILES | NC1CC1OS(=O)(=O)N1C[C@H](CCCB(O)O)[C@](N)(C(=O)O)C1 |
| InChI | InChI=1S/C11H22BN3O7S/c13-8-4-9(8)22-23(20,21)15-5-7(2-1-3-12(18)19)11(14,6-15)10(16)17/h7-9,18-19H,1-6,13-14H2,(H,16,17)/t7-,8?,9?,11-/m0/s1 |
| InChIKey | TZCZJQHGERRDLY-XVLZHWOZSA-N |
| XLogP | -2.69 |
| TPSA | 176.41 Ų |
| H-Bond Donors | 5 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 23 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 351.19 |
| LogP ≤ 5 | -2.69 |
| H-Bond Donors ≤ 5 | 5 |
| H-Bond Acceptors ≤ 10 | 8 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'heavy_metal', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155627301 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.